Specialty Drug Outcomes Metrics
| Drug Category | Clinical Outcome Metric | Financial Outcome Metric |
|---|---|---|
| Biologics (RA) | Disease activity score improvement | Reduction in RA-related hospitalizations |
| GLP-1 (diabetes) | HbA1c reduction; weight loss | Reduction in diabetes complications |
| Oncology | Response rate; progression-free survival | Total oncology cost per patient |
| MS drugs | Relapse rate reduction | Reduction in MS-related hospitalizations |
Discontinuation Criteria
Specialty drugs that do not achieve clinical response should be discontinued. A biologic for rheumatoid arthritis that does not improve disease activity scores after 3–6 months is not delivering clinical value — and costs $30,000–$80,000 per year. Clinical criteria for specialty drug continuation — requiring documented clinical response for continued coverage — can reduce specialty drug costs by 5–10%.
Outcomes-Based Contracts
IQ Insight
Outcomes-based contracts for specialty drugs tie payment to clinical outcomes. If the drug achieves the promised outcome (e.g., HbA1c reduction for a diabetes drug), the plan pays the full price. If the drug does not achieve the outcome, the manufacturer provides a rebate. Outcomes-based contracts are increasingly available for specialty drugs and provide financial protection against non-response.